Juan Gomez Rivas, Mark Taratkin, Camilla Azilgareeva, Andrey Morozov, Silvia Laso, Dmitry Enikeev, Jesús Moreno Sierra, Ksenia Schelkunova, Francesco Sanguedolce, Alberto Breda, Alexander Govorov, Alexander Vasilyev, Marcos Cepeda, Lukas Lusuardi, Maximilian Pallauf, Antonio Celia, Tommaso Silvestri, Cristian Fiori, Esaú Fernández, Juan Ignacio Martínez-Salamanca, Eric Barret
{"title":"冷冻疗法与根治性前列腺切除术作为放射复发前列腺癌的挽救治疗方法的比较","authors":"Juan Gomez Rivas, Mark Taratkin, Camilla Azilgareeva, Andrey Morozov, Silvia Laso, Dmitry Enikeev, Jesús Moreno Sierra, Ksenia Schelkunova, Francesco Sanguedolce, Alberto Breda, Alexander Govorov, Alexander Vasilyev, Marcos Cepeda, Lukas Lusuardi, Maximilian Pallauf, Antonio Celia, Tommaso Silvestri, Cristian Fiori, Esaú Fernández, Juan Ignacio Martínez-Salamanca, Eric Barret","doi":"10.1007/s00345-024-05199-4","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>The aim of this study is to compare outcomes of SRP (salvage radical prostatectomy) with SCAP (salvage cryoablation of the prostate) in local radio-recurrent PCa (prostate cancer) patients.</p><h3 data-test=\"abstract-sub-heading\">Materials and methods</h3><p>A retrospective analysis of a multicentric European Society of Uro-technology (ESUT) database was performed. Data on patients with local recurrent PCa after radiotherapy who underwent salvage treatment were collected. Patients and their respective disease characteristics, perioperative complications as well as oncological outcomes were then described. The treatment success rate was defined as PSA nadir < 0,4 ng/ml. Any complications were graded according to the modified Clavien system. A descriptive and comparative analysis was performed using SPSS software.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>25 patients underwent SRP and 71 patients received SCAP. The mean follow-up was 24 months. The median PSA level before initial treatment was 8.3 (range 7-127) ng/ml. The success rates of SRP and SCAP were largely comparable (88% (22 patients) vs. 67.7% (48 patients), respectively, <i>p</i> = 0.216). The mean serum PSA levels at 12 months after salvage treatment were 1.2 ± 0.2 ng/mL vs. 0.25 ± 0.5 ng/mL, <i>p</i> > 0.05). During the follow-up period, only 3 (12%) patients in the SRP group had PSA recurrence compared with 21 patients (29.6%) in the SCAP group. The 5-year BRFS was similar (51,6% and 48,2%, <i>p</i> = 0,08) for SRP and SCAP respectively. The 5-year overall survival rate was 91.7%, and 89,7% (<i>p</i> = 0.669) and the 5-year cancer-specific survival was 91.7%, and 97,1% (<i>p</i> = 0.077), after SRP and SCAP respectively. No difference was found regarding the complications.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Both SRP and SCAP should be considered as valid treatment options for patients with local recurrence of PCa after radiotherapy. SCAP has a potentially lower risk of morbidity and acceptable intermediate-term oncological efficacy, but a longer follow up and a higher number of patients is ideally needed to draw any long-term conclusions regarding the oncological data.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cryotherapy versus radical prostatectomy as a salvage treatment for radio-recurrent prostate cancer\",\"authors\":\"Juan Gomez Rivas, Mark Taratkin, Camilla Azilgareeva, Andrey Morozov, Silvia Laso, Dmitry Enikeev, Jesús Moreno Sierra, Ksenia Schelkunova, Francesco Sanguedolce, Alberto Breda, Alexander Govorov, Alexander Vasilyev, Marcos Cepeda, Lukas Lusuardi, Maximilian Pallauf, Antonio Celia, Tommaso Silvestri, Cristian Fiori, Esaú Fernández, Juan Ignacio Martínez-Salamanca, Eric Barret\",\"doi\":\"10.1007/s00345-024-05199-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Introduction</h3><p>The aim of this study is to compare outcomes of SRP (salvage radical prostatectomy) with SCAP (salvage cryoablation of the prostate) in local radio-recurrent PCa (prostate cancer) patients.</p><h3 data-test=\\\"abstract-sub-heading\\\">Materials and methods</h3><p>A retrospective analysis of a multicentric European Society of Uro-technology (ESUT) database was performed. Data on patients with local recurrent PCa after radiotherapy who underwent salvage treatment were collected. Patients and their respective disease characteristics, perioperative complications as well as oncological outcomes were then described. The treatment success rate was defined as PSA nadir < 0,4 ng/ml. Any complications were graded according to the modified Clavien system. A descriptive and comparative analysis was performed using SPSS software.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>25 patients underwent SRP and 71 patients received SCAP. The mean follow-up was 24 months. The median PSA level before initial treatment was 8.3 (range 7-127) ng/ml. The success rates of SRP and SCAP were largely comparable (88% (22 patients) vs. 67.7% (48 patients), respectively, <i>p</i> = 0.216). The mean serum PSA levels at 12 months after salvage treatment were 1.2 ± 0.2 ng/mL vs. 0.25 ± 0.5 ng/mL, <i>p</i> > 0.05). During the follow-up period, only 3 (12%) patients in the SRP group had PSA recurrence compared with 21 patients (29.6%) in the SCAP group. The 5-year BRFS was similar (51,6% and 48,2%, <i>p</i> = 0,08) for SRP and SCAP respectively. The 5-year overall survival rate was 91.7%, and 89,7% (<i>p</i> = 0.669) and the 5-year cancer-specific survival was 91.7%, and 97,1% (<i>p</i> = 0.077), after SRP and SCAP respectively. No difference was found regarding the complications.</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusions</h3><p>Both SRP and SCAP should be considered as valid treatment options for patients with local recurrence of PCa after radiotherapy. SCAP has a potentially lower risk of morbidity and acceptable intermediate-term oncological efficacy, but a longer follow up and a higher number of patients is ideally needed to draw any long-term conclusions regarding the oncological data.</p>\",\"PeriodicalId\":23954,\"journal\":{\"name\":\"World Journal of Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00345-024-05199-4\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00345-024-05199-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Cryotherapy versus radical prostatectomy as a salvage treatment for radio-recurrent prostate cancer
Introduction
The aim of this study is to compare outcomes of SRP (salvage radical prostatectomy) with SCAP (salvage cryoablation of the prostate) in local radio-recurrent PCa (prostate cancer) patients.
Materials and methods
A retrospective analysis of a multicentric European Society of Uro-technology (ESUT) database was performed. Data on patients with local recurrent PCa after radiotherapy who underwent salvage treatment were collected. Patients and their respective disease characteristics, perioperative complications as well as oncological outcomes were then described. The treatment success rate was defined as PSA nadir < 0,4 ng/ml. Any complications were graded according to the modified Clavien system. A descriptive and comparative analysis was performed using SPSS software.
Results
25 patients underwent SRP and 71 patients received SCAP. The mean follow-up was 24 months. The median PSA level before initial treatment was 8.3 (range 7-127) ng/ml. The success rates of SRP and SCAP were largely comparable (88% (22 patients) vs. 67.7% (48 patients), respectively, p = 0.216). The mean serum PSA levels at 12 months after salvage treatment were 1.2 ± 0.2 ng/mL vs. 0.25 ± 0.5 ng/mL, p > 0.05). During the follow-up period, only 3 (12%) patients in the SRP group had PSA recurrence compared with 21 patients (29.6%) in the SCAP group. The 5-year BRFS was similar (51,6% and 48,2%, p = 0,08) for SRP and SCAP respectively. The 5-year overall survival rate was 91.7%, and 89,7% (p = 0.669) and the 5-year cancer-specific survival was 91.7%, and 97,1% (p = 0.077), after SRP and SCAP respectively. No difference was found regarding the complications.
Conclusions
Both SRP and SCAP should be considered as valid treatment options for patients with local recurrence of PCa after radiotherapy. SCAP has a potentially lower risk of morbidity and acceptable intermediate-term oncological efficacy, but a longer follow up and a higher number of patients is ideally needed to draw any long-term conclusions regarding the oncological data.
期刊介绍：
The WORLD JOURNAL OF UROLOGY conveys regularly the essential results of urological research and their practical and clinical relevance to a broad audience of urologists in research and clinical practice. In order to guarantee a balanced program, articles are published to reflect the developments in all fields of urology on an internationally advanced level. Each issue treats a main topic in review articles of invited international experts. Free papers are unrelated articles to the main topic.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
